Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial

American Heart Journal

Volumn 154, Issue 1, 2007, Pages 158.e1-158.e7

  Mehilli, Julinda ^a   Ndrepepa, Gjin ^a   Kastrati, Adnan ^a   Neumann, Franz Josef ^c   ten Berg, Jurriën ^d   Bruskina, Olga ^a   Dotzer, Franz ^e   Seyfarth, Melchior ^a   Pache, Jürgen ^a   Kufner, Sebastian ^a   Dirschinger, Josef ^b   Berger, Peter B ^f   Schömig, Albert ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e Klinikum Garmisch Partenkirchen   (Germany)

^f GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; PLACEBO;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG EFFECT; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 34250311693     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.050     Document Type: Article

References (31)

1. Furman M.I., Dauerman H.L., Goldberg R.J., et al. Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol 37 (2001) 1571-1580
2. Grech E.D., and Ramsdale D.R. Acute coronary syndrome: ST segment elevation myocardial infarction. BMJ 326 (2003) 1379-1381
3. Neumann F.J., Kastrati A., Pogatsa-Murray G., et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 1593-1599
4. Mehilli J., Kastrati A., Schühlen H., et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110 (2004) 3627-3635
5. Kastrati A., Mehilli J., Schühlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
6. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
7. Malenka D.J., O'Connor G.T., Quinton H., et al. Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13,061 procedures. Northern New England Cardiovascular Disease Study Group. Circulation 94 9 Suppl (1996) II99-II104
8. Mehilli J., Kastrati A., Dirschinger J., et al. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA 284 (2000) 1799-1805
9. Peterson E.D., Lansky A.J., Kramer J., et al. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am J Cardiol 88 (2001) 359-364
10. Jacobs A.K., Johnston J.M., Haviland A., et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol 39 (2002) 1608-1614
11. Alexander K.P., Chen A.Y., Newby L.K., et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 114 (2006) 1380-1387
12. Alexander K.P., Chen A.Y., Roe M.T., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
13. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359 (2002) 189-198
14. Fernandes L.S., Tcheng J.E., O'Shea J.C., et al. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol 40 (2002) 1085-1091
15. Malacrida R., Genoni M., Maggioni A.P., et al. A comparison of the early outcome of acute myocardial infarction in women and men. The Third International Study of Infarct Survival Collaborative Group. N Engl J Med 338 (1998) 8-14
16. Abramson JL, Veledar E, Weintraub WS et al. Association between gender and in-hospital mortality after percutaneous coronary intervention according to age. Am J Cardiol 2003;91:968-971, A964.
17. Marrugat J., Sala J., Masia R., et al. Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera. JAMA 280 (1998) 1405-1409
18. Müller I., Seyfarth M., Rüdiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85 (2001) 92-93
19. Cho L., Topol E.J., Balog C., et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 36 (2000) 381-386
20. Iakovou I., Dangas G., Mehran R., et al. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Am J Cardiol 89 (2002) 976-979
21. Iakovou I., Dangas G., Mintz G.S., et al. Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Am J Cardiol 93 (2004) 346-349
22. Ndrepepa G., Kastrati A., Mehilli J., et al. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation 114 (2006) 2040-2046
23. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98 (1998) 2695-2701
24. Pepine C.J., Kerensky R.A., Lambert C.R., et al. Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol 47 3 Suppl (2006) S30-S35
25. Dibra A., Mehilli J., Dirschinger J., et al. Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. J Am Coll Cardiol 41 (2003) 925-929
26. Gibson C.M., Murphy S.A., Rizzo M.J., et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis in Myocardial Infarction (TIMI) Study Group. Circulation 99 (1999) 1945-1950
27. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
28. Moscucci M., Fox K.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
29. Berkowitz S.D., Granger C.B., Pieper K.S., et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 95 (1997) 2508-2516
30. Lenderink T., Boersma E., Ruzyllo W., et al. Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. Am Heart J 147 (2004) 865-873
31. Freeman R.V., Mehta R.H., Al Badr W., et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41 (2003) 718-724